These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 15663994)

  • 1. Interaction of nuclear receptor ligands with the Vitamin D signaling pathway in prostate cancer.
    Peehl DM; Feldman D
    J Steroid Biochem Mol Biol; 2004 Nov; 92(4):307-15. PubMed ID: 15663994
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Androgen receptor signaling and vitamin D receptor action in prostate cancer cells.
    Murthy S; Agoulnik IU; Weigel NL
    Prostate; 2005 Sep; 64(4):362-72. PubMed ID: 15754350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interaction of nuclear receptors with the Wnt/beta-catenin/Tcf signaling axis: Wnt you like to know?
    Mulholland DJ; Dedhar S; Coetzee GA; Nelson CC
    Endocr Rev; 2005 Dec; 26(7):898-915. PubMed ID: 16126938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-genomic effects of the androgen receptor and vitamin D agonist are involved in suppressing invasive phenotype of prostate cancer cells.
    Bonaccorsi L; Marchiani S; Ferruzzi P; Muratori M; Crescioli C; Forti G; Maggi M; Baldi E
    Steroids; 2006 Apr; 71(4):304-9. PubMed ID: 16289173
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interactions between vitamin D and androgen receptor signaling in prostate cancer cells.
    Weigel NL
    Nutr Rev; 2007 Aug; 65(8 Pt 2):S116-7. PubMed ID: 17867385
    [No Abstract]   [Full Text] [Related]  

  • 6. Cholecalciferol (vitamin D3) inhibits growth and invasion by up-regulating nuclear receptors and 25-hydroxylase (CYP27A1) in human prostate cancer cells.
    Tokar EJ; Webber MM
    Clin Exp Metastasis; 2005; 22(3):275-84. PubMed ID: 16158255
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vitamin D in prostate cancer.
    Trump DL; Aragon-Ching JB
    Asian J Androl; 2018; 20(3):244-252. PubMed ID: 29667615
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vitamin D in Prostate Cancer.
    Ahn J; Park S; Zuniga B; Bera A; Song CS; Chatterjee B
    Vitam Horm; 2016; 100():321-55. PubMed ID: 26827958
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vitamin D and prostate cancer: biologic interactions and clinical potentials.
    Miller GJ
    Cancer Metastasis Rev; 1998-1999; 17(4):353-60. PubMed ID: 10453279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Androgen receptor signaling in prostate cancer.
    Culig Z; Santer FR
    Cancer Metastasis Rev; 2014 Sep; 33(2-3):413-27. PubMed ID: 24384911
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 1alpha,25-dihydroxyvitamin D3 inhibits prostate cancer cell growth by androgen-dependent and androgen-independent mechanisms.
    Zhao XY; Peehl DM; Navone NM; Feldman D
    Endocrinology; 2000 Jul; 141(7):2548-56. PubMed ID: 10875257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuroendocrine differentiation in prostate carcinoma: focusing on its pathophysiologic mechanisms and pathological features.
    Alberti C
    G Chir; 2010; 31(11-12):568-74. PubMed ID: 21232206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Androgen signaling is required for the vitamin D-mediated growth inhibition in human prostate cancer cells.
    Bao BY; Hu YC; Ting HJ; Lee YF
    Oncogene; 2004 Apr; 23(19):3350-60. PubMed ID: 15048085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advances in the development of retinoids as chemopreventive agents.
    Lippman SM; Lotan R
    J Nutr; 2000 Feb; 130(2S Suppl):479S-482S. PubMed ID: 10721933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanistic concepts in androgen-dependence of prostate cancer.
    Craft N; Sawyers CL
    Cancer Metastasis Rev; 1998-1999; 17(4):421-7. PubMed ID: 10453286
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elevated NCOR1 disrupts PPARalpha/gamma signaling in prostate cancer and forms a targetable epigenetic lesion.
    Battaglia S; Maguire O; Thorne JL; Hornung LB; Doig CL; Liu S; Sucheston LE; Bianchi A; Khanim FL; Gommersall LM; Coulter HS; Rakha S; Giddings I; O'Neill LP; Cooper CS; McCabe CJ; Bunce CM; Campbell MJ
    Carcinogenesis; 2010 Sep; 31(9):1650-60. PubMed ID: 20466759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The expression of glucocorticoid receptor is negatively regulated by active androgen receptor signaling in prostate tumors.
    Xie N; Cheng H; Lin D; Liu L; Yang O; Jia L; Fazli L; Gleave ME; Wang Y; Rennie P; Dong X
    Int J Cancer; 2015 Feb; 136(4):E27-38. PubMed ID: 25138562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of proliferation and induction of apoptosis by 25-hydroxyvitamin D3-3beta-(2)-Bromoacetate, a nontoxic and vitamin D receptor-alkylating analog of 25-hydroxyvitamin D3 in prostate cancer cells.
    Swamy N; Chen TC; Peleg S; Dhawan P; Christakos S; Stewart LV; Weigel NL; Mehta RG; Holick MF; Ray R
    Clin Cancer Res; 2004 Dec; 10(23):8018-27. PubMed ID: 15585637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathways mediating the growth-inhibitory actions of vitamin D in prostate cancer.
    Peehl DM; Krishnan AV; Feldman D
    J Nutr; 2003 Jul; 133(7 Suppl):2461S-2469S. PubMed ID: 12840225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways.
    Vis AN; Schröder FH
    BJU Int; 2009 Aug; 104(4):438-48. PubMed ID: 19558559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.